Dr. Todd Morgan

Yeah, like never. And so patients, I'm sure you have this experience too, or say, well, so then will I be cured or am I cured? And I just, I always say, and I say, you know, cure is a term that we just like all of us oncologists just really have a hard time saying, because pretty much everybody with a history of cancer has, of any kind of cancer, has some risk of that cancer coming back.

Yeah, like never. And so patients, I'm sure you have this experience too, or say, well, so then will I be cured or am I cured? And I just, I always say, and I say, you know, cure is a term that we just like all of us oncologists just really have a hard time saying, because pretty much everybody with a history of cancer has, of any kind of cancer, has some risk of that cancer coming back.

And that risk may be really, really, really low so that we kind of in lay terms use words like cure, but Really, we tend to rely on a little bit more technical things, which sound awkward, like no evidence of disease. And basically, if we're getting two years, three years, four years out, and no evidence of recurrence, no evidence of disease, we're feeling really, really good, really optimistic.

And that risk may be really, really, really low so that we kind of in lay terms use words like cure, but Really, we tend to rely on a little bit more technical things, which sound awkward, like no evidence of disease. And basically, if we're getting two years, three years, four years out, and no evidence of recurrence, no evidence of disease, we're feeling really, really good, really optimistic.

And that risk may be really, really, really low so that we kind of in lay terms use words like cure, but Really, we tend to rely on a little bit more technical things, which sound awkward, like no evidence of disease. And basically, if we're getting two years, three years, four years out, and no evidence of recurrence, no evidence of disease, we're feeling really, really good, really optimistic.

And often, even times after surgery, when the pathology looks really encouraging, we're feeling really optimistic. And by the way, good news, we have this test PSA, which is despite all of its flaws in the screening setting, is an unbelievable biomarker in the post-operative setting.

And often, even times after surgery, when the pathology looks really encouraging, we're feeling really optimistic. And by the way, good news, we have this test PSA, which is despite all of its flaws in the screening setting, is an unbelievable biomarker in the post-operative setting.

And often, even times after surgery, when the pathology looks really encouraging, we're feeling really optimistic. And by the way, good news, we have this test PSA, which is despite all of its flaws in the screening setting, is an unbelievable biomarker in the post-operative setting.

Yeah. Do you ever, do you use it? Do you say, I think we've carried you or it seems, sure seems like we've carried you?

Yeah. Do you ever, do you use it? Do you say, I think we've carried you or it seems, sure seems like we've carried you?

Yeah. Do you ever, do you use it? Do you say, I think we've carried you or it seems, sure seems like we've carried you?

So all high risk and most, but not all unfavorable intermediate risk. Okay, no issues with coverage, that's all kind of... No, yeah, it seems like we're doing just fine there. So it's certainly replaced CT and bone scan for all these patients. You know, an unfavorable intermediate risk can be reasonably heterogeneous, right?

So all high risk and most, but not all unfavorable intermediate risk. Okay, no issues with coverage, that's all kind of... No, yeah, it seems like we're doing just fine there. So it's certainly replaced CT and bone scan for all these patients. You know, an unfavorable intermediate risk can be reasonably heterogeneous, right?

So all high risk and most, but not all unfavorable intermediate risk. Okay, no issues with coverage, that's all kind of... No, yeah, it seems like we're doing just fine there. So it's certainly replaced CT and bone scan for all these patients. You know, an unfavorable intermediate risk can be reasonably heterogeneous, right?

You have one core at 4 plus 3 and a PSA at 5, or you have higher volume, higher PSA. I tend not to get it on all unfavorable intermediate risk.

You have one core at 4 plus 3 and a PSA at 5, or you have higher volume, higher PSA. I tend not to get it on all unfavorable intermediate risk.

You have one core at 4 plus 3 and a PSA at 5, or you have higher volume, higher PSA. I tend not to get it on all unfavorable intermediate risk.

And I think radiation oncologists have a little bit of an earlier trigger to get a PSMA PET, which makes good sense. It's going to maybe impact their treatment plan. And so let's say there's a 3% chance of a positive finding in some of these settings. But maybe that 3% is worth it in the setting of a patient undergoing radiation.

And I think radiation oncologists have a little bit of an earlier trigger to get a PSMA PET, which makes good sense. It's going to maybe impact their treatment plan. And so let's say there's a 3% chance of a positive finding in some of these settings. But maybe that 3% is worth it in the setting of a patient undergoing radiation.

And I think radiation oncologists have a little bit of an earlier trigger to get a PSMA PET, which makes good sense. It's going to maybe impact their treatment plan. And so let's say there's a 3% chance of a positive finding in some of these settings. But maybe that 3% is worth it in the setting of a patient undergoing radiation.